TOP study prospectively shows TP53-mutant EGFR lung cancer gains from first-line combination therapy, reshaping choices amid FLAURA2 and MARIPOSA.
The TOP Study and Beyond — TP53 as a Treatment-Selection Biomarker in First-Line EGFR-Mutant NSCLC
Experts unpack TOP trial data on TP53 co-mutations, guiding first-line EGFR lung cancer choices between osimertinib alone or with chemo.
Advertisement
Advertisement
Trending on OncLive
1
MAIC Shows OS Benefit With Mogamulizumab vs Vorinostat in Cutaneous T-Cell Lymphoma Subtypes
2
QOL, Efficacy, and Cost Considerations Help Drive TKI Treatment Selection in CML
3
From "Not Curable" to "May Be Curable": Joshua Richter, MD, on the New Reality of Multiple Myeloma
4
Revised Risk Stratifications Help Inform the Use of Adjuvant Cemiplimab and Neoadjuvant Strategies in Cutaneous Squamous Cell Carcinoma
5